why choose us

First received: March 28, 2023

Clinical Trial: REVERSE-Long COVID-19 With Baricitinib Pilot Study

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Post-Acute COVID-19 Syndrome

Study Type: INTERVENTIONAL


Official Title: REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease an

Brief Summary: This is a pilot study for REVERSE-LC, a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

Read more